The SPRING Study (NCT04070326) was a phase 3 study that investigated the safety, pharmacokinetics, and pharmacodynamics of lanadelumab for prevention of hereditary angioedema (HAE) attacks in children. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the aims, design and findings from the SPRING Study and how insights from the trial will optimise the use of lanadelumab in clinical practice following the recent approval by the FDA in paediatric patients aged 2 to <12 years with HAE.
The abstract ‘Efficacy of lanadelumab at fixed and modified dosing regimens in patients aged 2 to <12 years old with hereditary angioedema (HAE) in the phase 3, open-label, multicenter SPRING Study.‘ (Abstract number: AB140) was presented at AAAAI 2023, February 24–27, 2022, #AAAAI2023.
Questions
- What were the aims, design and inclusion criteria of the SPRING Study? (0:42)
- What were the primary and secondary outcome measures and how well were these achieved? (3:13)
- How will these insights optimise our use of lanadelumab? (5:10)
- What will the recent approval of lanadelumab in paediatric patients aged 2 to <12 years mean for clinical practice? (7:16)
Disclosures: William R. Lumry discloses consulting for: Astria, BioCryst, Biomarin, CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia, Kalvista, Magellan, Optum, Pharming, Pharvaris, and Shire/Takeda; receiving grant/research support from: Astria, BioMarin, CSL Behring, Intellia, Grifols, Ionis, Kalvista, and Shire/Takeda; serving on advisory boards for: Astria, BioCryst, Biomarin, CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia, Kalvista, Magellan, Optum, Pharming, Pharvaris, and Shire/Takeda; receiving honoraria for consultancy and speaker’s bureaus and participating in speaker’s bureaus with: BioCryst, CSL Behring, Optinose, Pharming, Shire/Takeda, Grifols, Astra Zeneca, Sanofi/Regeneron, and GSK.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the American Academy of Allergy Asthma & Immunology Annual Meeting 2023.
Click here for more content on allergic conditions.
